1. Home
  2. Age-Related Macular Degeneration (ARMD) Doctors Near Me
  3. Treatments
  4. Verteporfin

Age-Related Macular Degeneration (ARMD) Treatments

Find Age-Related Macular Degeneration (ARMD) Treatments

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments
Brand Name

Visudyne

Generic Name
Verteporfin
View Brand Information
FDA approval date: April 12, 2000
Classification: Photoenhancer
Form: Injection

What is Visudyne (Verteporfin)?

VISUDYNE ® therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration , pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV. VISUDYNE therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Approved To Treat

  • Late-Onset Retinal Degeneration
  • Age-Related Macular Degeneration (ARMD)
  • Nearsightedness

Top Global Experts

  • Carol L. Shields
    Carol L. Shields
  • Peter Kaiser
    Peter Kaiser
  • Jay Chhablani
    Jay Chhablani
  • Ursula M. Erfurth-Schmidt
    Ursula M. Erfurth-Schmidt
  • Giuseppe Querques
    Giuseppe Querques
View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Phase I/II Study of Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients With Inoperable Malignant Central Airway Obstruction
A Phase I/II Study of Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients With Inoperable Malignant Central Airway Obstruction
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Procedure, Drug, Other, Device, Radiation
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or...

Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic Cancer
Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: January 30, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Phase: Phase 2

Summary: This phase II trial tests how well photoradiation with verteporfin and pembrolizumab plus standard of care chemotherapy works in treating patients with pancreatic cancer that cannot be removed by surgery (unresectable), that has spread to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic). Photoradiation uses light activated drugs, such as verteporfin, that...

Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer
Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer
Enrollment Status: Recruiting
Publish Date: December 18, 2025
Intervention Type: Device, Drug
Study Phase: Phase 1/Phase 2

Summary: The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose,...

View All Clinical Trials

Related Latest Advances

Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.
Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.
Journal: Translational vision science & technology
Published: April 13, 2026
Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.
Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: March 03, 2026
Cyanidin-3-O-glucoside chloride inhibits cartilage degeneration and inflammation in TMJOA via YAP/NF-κB signaling pathway.
Cyanidin-3-O-glucoside chloride inhibits cartilage degeneration and inflammation in TMJOA via YAP/NF-κB signaling pathway.
Journal: Food & function
Published: February 23, 2026
View All Latest Advances
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved